New schizophrenia drug shows promise in major trial

NCT ID NCT04072354

Completed Disease control Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an investigational drug called SEP-363856 in 463 people with schizophrenia who were having severe symptoms. Participants received either the drug or a placebo for 6 weeks. The main goal was to see if the drug reduced symptoms like hallucinations and emotional withdrawal better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Research Site

Little Rock, Arkansas, 72211, United States
Research Site

Anaheim, California, 92805, United States
Research Site

Bellflower, California, 90706, United States
Research Site

Lemon Grove, California, 91945, United States
Research Site

Long Beach, California, 90807, United States
Research Site

Montclair, California, 91763, United States
Research Site

Pico Rivera, California, 90660, United States
Research Site

San Diego, California, 92103, United States
Research Site

Hollywood, Florida, 33021, United States
Research Site

Hollywood, Florida, 33024, United States
Research Site

Miami Springs, Florida, 33166, United States
Research Site

Atlanta, Georgia, 30318, United States
Research Site

Atlanta, Georgia, 30331, United States
Research Site

Decatur, Georgia, 30030, United States
Research Site

Gaithersburg, Maryland, 20877, United States
Research Site

Flowood, Mississippi, 39232, United States
Research Site

Dayton, Ohio, 45417, United States
Research Site

Austin, Texas, 78754, United States
Research Site

Pazardzhik, 4400, Bulgaria
Research Site

Pleven, 5800, Bulgaria
Research Site

Sofia, 1202, Bulgaria
Research Site

Sofia, 1431, Bulgaria
Research Site

Veliko Tarnovo, 5000, Bulgaria
Research Site

Vratsa, 3000, Bulgaria
Research Site

Bello, Antioquia, 051053, Colombia
Research Site

Bogotá, 111166, Colombia
Research Site

Bogotá, Colombia
Research Site

Chelyabinsk, 454087, Russia
Research Site

Moscow, 107076, Russia
Research Site

Nizniy Novgorod, 603155, Russia
Research Site

Petrozavodsk, 186131, Russia
Research Site

Saint Petersburg, 092019, Russia
Research Site

Saint Petersburg, 192019, Russia
Research Site

Samara, 443016, Russia
Research Site

Saratov, 410028, Russia
Research Site

Belgrade, 11000, Serbia
Research Site

Gornja Toponica, 18202, Serbia
Research Site

Kovin, 26220, Serbia
Research Site

Kragujevac, 34000, Serbia
Research Site

Niš, 18000, Serbia
Research Site

Novi Kneževac, 23330, Serbia
Research Site

Novi Sad, 21000, Serbia
Research Site

Vršac, 26300, Serbia
Research Site

Ivano-Frankivsk, 76011, Ukraine
Research Site

Kropyvnytskyi, 25491, Ukraine
Research Site

Kyiv, 02192, Ukraine
Research Site

Kyiv, 04080, Ukraine
Research Site

Lviv, 79021, Ukraine
Research Site

Odesa, 65006, Ukraine
Research Site

Odesa, 67513, Ukraine
Research Site

Poltava, 36013, Ukraine
Research Site

Smila, 20708, Ukraine
Research Site

Vinnytsia, 21005, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.